Advertisement

Document › Details
Owlstone Medical Ltd.. (10/10/18). "Press Release: Owlstone Medical Appoints Dr Richard A Yost to Scientific Advisory Board". Cambridge.
![]() |
Organisation | Owlstone Medical Ltd. |
Group | Owlstone (Group) | |
Organisation 2 | University of Florida | |
![]() |
Product | Breath Biopsy® platform |
Product 2 | triple quadrupole mass spectrometer | |
![]() |
Person | Yost, Richard A. (Univ Florida 201406 Head of Analytical Chemistry) |
Person 2 | Boyle, Billy (Owlstone 201606 CEO + Co-Founder of Owlstone Medical Ltd) | |
Owlstone Medical (or the “Company”), a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, today announces the appointment of Dr. Richard A Yost to its Scientific Advisory Board.
Dr. Yost, Professor and Head of Analytical Chemistry at the University of Florida, is an internationally recognized leader in the field of analytical chemistry. He has particular expertise in tandem mass spectrometry and is the co-inventor of the triple quadrupole mass spectrometer, which today represents over $1 billion in sales each year.
His research has been recognized with the highest award in the field, receiving the 1993 ASMS Award for Distinguished Contribution in Mass Spectrometry, as well as the 2018 MSACL Award for Distinguished Contribution in Clinical Mass Spectrometry. He currently serves as the President of ASMS, the 7,000-member American Society for Mass Spectrometry.
Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “Owlstone Medical has invested in building a world class mass spec capability as part of our Breath Biopsy® discovery offering. We make this available to our academic and pharma partners conducting breath VOC research in a range of applications. We are fortunate to now be able to benefit from Richard’s extraordinary mass spec and metabolomics expertise, and I am very pleased to welcome him to our SAB.”
Breath Biopsy Conference 2018 is Owlstone Medical's inaugural community meeting for breath researchers. https://www.owlstonemedical.com/about/events/breath-biopsy-conference-2018/
ENDS
Notes to Editors
Full biography:
Dr. Richard A Yost
Dr. Yost is a Professor and Head of Analytical Chemistry at the University of Florida. He is an internationally recognized leader in the field of analytical chemistry, particularly tandem mass spectrometry (MS/MS), and is best known for co-inventing the triple quadrupole mass spectrometer as a graduate student at Michigan State University.
Dr. Yost's professional activities have focused on research and teaching in analytical mass spectrometry, and his group’s research has reflected a unique balance between instrumentation development, fundamental studies, and applications in analytical chemistry. Their work has led to the development of novel applications of mass spectrometry in areas such as metabolomics, clinical, biomedical, pharmaceutical, environmental, and forensic chemistry, and has resulted in over 210 publications and more than 25 patents. Dr. Yost has supervised the research of over 115 graduate students during his almost 40-year career, and has served as Principal Investigator (PI) or Co-PI on grants and contracts totaling over $50 million of funding. His research has been recognized with the highest award in his discipline, the 1993 ASMS Award for Distinguished Contribution in Mass Spectrometry, as well as the 2018 MSACL Award for Distinguished Contribution in Clinical Mass Spectrometry. He currently serves as the President of ASMS, the 7,000-member American Society for Mass Spectrometry.
Dr Richard A Yost
For a high resolution image please contact sarah.jeffery@zymecommunications.com
For more information please contact:
Owlstone Medical
Chris Claxton, Head of Investor Relations
chris.claxton@owlstone.co.uk
Media relations:
Sarah Jeffery, Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0)7771 730919
About Owlstone Medical
www.owlstonemedical.com
Owlstone Medical’s vision is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®. Breath Biopsy operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources such as diet or medication, changes in which can be characteristic of specific disease or indicate environmental exposure.
The Breath Biopsy platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, UK, and the development of the world’s largest Digital Breath Biobank matched to patient phenotype.
Owlstone Medical is deploying the platform to address some of the key challenges of 21st century healthcare. The focus is on the early detection of disease with an emphasis on cancer, with clinical trials underway to develop breath tests for the early detection of lung and colorectal cancer, and on precision medicine through partnerships with large pharmaceutical companies including AstraZeneca and GlaxoSmithKline to enable therapeutics to be deployed more effectively. Owlstone Medical’s technology is currently in use at over 100 sites worldwide.
Record changed: 2023-06-05 |
Advertisement

More documents for Owlstone (Group)
- [1] Owlstone Medical Ltd.. (3/15/23). "Press Release: Owlstone Medical Enters Partnership with Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection". Cambridge....
- [2] Owlstone Medical Ltd.. (9/7/21). "Press Release: Owlstone Medical Closes $58 Million USD (c. £42 Million GBP) Oversubscribed Financing Round to Continue to Advance Breath Biopsy". Cambridge....
- [3] Owlstone Medical Ltd.. (3/30/20). "Press Release: Owlstone Medical Appoints Neil Tween as Chief Financial Officer". Cambridge....
- [4] Owlstone Medical Ltd.. (11/7/19). "Press Release: Owlstone Medical Enters Partnership with Thermo Fisher Scientific to Advance Early Disease Detection Using Non-invasive Breath Biopsy". Cambridge....
- [5] Owlstone Medical Ltd.. (9/5/19). "Press Release: Owlstone Medical Announces Advancements in Breath Biopsy Platform Including Launch of Next Generation ReCIVA Breath Sampler and CASPER Portable Air Supply". Cambridge....
- [6] Owlstone Medical Ltd.. (6/18/19). "Press Release: Owlstone Medical Announces a Novel Approach to Breath-Based Testing for Investigation of the Onset, Progression, and Treatment of Disease". Cambridge....
- [7] Owlstone Medical Ltd.. (6/5/19). "Press Release: Owlstone Medical and the International Association of Heat and Frost Insulators and Allied Workers Partner to Identify Breath Biomarkers for the Early Detection of Malignant Mesothelioma". Cambridge & Lanh...
- [8] Owlstone Medical Ltd.. (5/20/19). "Press Release: Owlstone Medical Enters into a Strategic Collaboration with Actelion to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension". Cambridge....
- [9] Owlstone Medical Ltd.. (3/7/19). "Press Release: University of Manchester and Owlstone Medical Partner on £250,000 Grant from Asthma UK and Innovate UK for Asthma Diagnostic Development". Manchester & Cambridge....
- [10] Owlstone Medical Ltd.. (10/1/18). "Press Release: Owlstone Medical Completes $50 Million USD (c.£38 Million GBP) Financing Round". Cambridge....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement

» top